DOI | Trouver le DOI : https://doi.org/10.1016/j.biotechadv.2008.10.003 |
---|
Auteur | Rechercher : Dormond, E.1; Rechercher : Perrier, M.; Rechercher : Kamen, A.1 |
---|
Affiliation | - Conseil national de recherches du Canada. Institut de recherche en biotechnologie du CNRC
|
---|
Format | Texte, Article |
---|
Sujet | biotechnology; cell culture; gene therapy; therapy; adenovirus; helper-dependent adenoviral vector; production; quantification |
---|
Résumé | Human adenoviral viral vector serotype 5 (AdV) is presently the primary viral vector used in gene therapy trials. Advancements in AdV process development directly contribute to the clinical application and commercialization of the AdV gene delivery technology. Notably, the development of AdV production in suspension culture has driven the increase in AdV volumetric and specific productivity, therefore providing large quantities of AdV required for clinical studies. This review focuses on detailing the viral, cell and cell culture parameters governing the productivity of the three generations of AdV vectors. |
---|
Date de publication | 2008-10-31 |
---|
Dans | |
---|
Langue | anglais |
---|
Numéro du CNRC | NRCC 47833 |
---|
Numéro NPARC | 12390838 |
---|
Exporter la notice | Exporter en format RIS |
---|
Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
---|
Identificateur de l’enregistrement | cbc7bc8a-f1be-4037-85a2-bf93bcc62815 |
---|
Enregistrement créé | 2009-10-26 |
---|
Enregistrement modifié | 2020-04-15 |
---|